U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07403097) titled 'Study of CD19 CAR-T Therapy for Refractory SLE' on Feb. 04.
Brief Summary: This is an investigator-initiated trial aimed at assessing the safety and efficacy of PTOC1 cells Injection in the treatment of refractory systemic lupus erythematosus.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
BIOLOGICAL: PTOC1
Three dose groups (1.5x10^5/kg, 5x10^5/kg,1x10^6/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
Recruitment Status: RECRUITING
Sponsor: Chongqing Precision Biotech Co., Ltd
Disclaimer: Curated by HT Syndica...